The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.

NCT05732129 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer

Interventions

DRUG: Fluzoparib
DRUG: Irinotecan

Sponsor

Fudan University